DBV
DBV TECHNOLOGIES
Stock Euronext / Paris – Stock Market Prices, News & Analysis
DBV Biotech (DBV Technologies) is a French biotech company specializing in epicutaneous immunotherapy for food allergies through its Viaskin® platform, notably the Viaskin Peanut (peanut) and Viaskin Milk patches, with ongoing clinical programs (Viaskin Egg in preclinical). The EPIT technology delivers micro-doses of allergens through the skin to retrain the immune system. The company is led by CEO Daniel Tassé and among its founders are Pierre-Henri Benhamou, Bertrand, and Christophe Dupont. Its flagship patch, Viaskin Peanut, is progressing towards a Biologics License Application (BLA) with the FDA following promising Phase 3 results.
DBV TECHNOLOGIES
DBV
DBV Biotech (DBV Technologies) is a French biotech company specializing in epicutaneous immunotherapy for food allergies through its Viaskin® platform, notably the Viaskin Peanut (peanut) and Viaskin Milk patches, with ongoing clinical programs (Viaskin Egg in preclinical). The EPIT technology delivers micro-doses of allergens through the skin to retrain the immune system. The company is led by CEO Daniel Tassé and among its founders are Pierre-Henri Benhamou, Bertrand, and Christophe Dupont. Its flagship patch, Viaskin Peanut, is progressing towards a Biologics License Application (BLA) with the FDA following promising Phase 3 results.
Anantys Community
Anantys Community
2 members hold DBV TECHNOLOGIES with an average return of 110.0%. Join them to follow signals and build your long-term investment strategy.
Price history of DBV TECHNOLOGIES
Price history of DBV TECHNOLOGIES
Performance & Momentum
J.P. Morgan Chase Exceeds 10% Stake in DBV Technologies
On January 8, 2026, J.P. Morgan Chase announced indirect ownership of over 10% of the share capital and voting rights of DBV Technologies, indicating increased interest from a key institutional player. This significant stake may explain the notable rise in the share price, reflecting renewed or strengthened confidence from institutional investors.
Strategic Analysis
DBV TECHNOLOGIES • 2026
DBV Technologies positions itself as an innovative player in epicutaneous immunotherapy, developing targeted solutions for food allergies through its Viaskin® platform. Its differentiation is based on a patented technology that delivers allergens through the skin, providing a promising and non-invasive approach to desensitization.
Strengths
- Unique and protected EPIT technology, validated by advanced clinical trials
- Product pipeline with Viaskin Peanut in the final stage of regulatory approval with the FDA
- Increased strategic and financial support, as evidenced by the significant investment from J.P. Morgan Chase
Weaknesses
- Dependence on key regulatory approvals for commercialization
- Volatile long-term financial performance history weighing on confidence
Momentum
The momentum is very strong, driven by positive clinical results and notable financial interest from a major player like J.P. Morgan Chase, bolstering confidence in imminent commercial potential. This dynamic supports a favorable medium-term outlook, although it is reliant on the success of regulatory processes.
Similar stocks to DBV TECHNOLOGIES
Take control
of your investments
Track your portfolios, analyze your performance and receive personalized insights to invest with strategy.
- Real-time multi-portfolio tracking
- AI analysis of your positions
- Counter your cognitive biases
